Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis

EBioMedicine

Volumn 2, Issue 11, 2015, Pages 1640-1649

  Shenje, Justin ^a   Ifeoma Adimora Nweke, F ^b   Ross, Ian L ^a   Ntsekhe, Mpiko ^a   Wiesner, Lubbe ^a   Deffur, Armin ^a   McIlleron, Helen M ^a   Pasipanodya, Jotam ^b   Gumbo, Tawanda ^a,b   Mayosi, Bongani M ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b BAYLOR RESEARCH INSTITUTE   (United States)

Author keywords

Drug penetration; Ethambutol; Pericardium; Protein binding; Pyrazinamide; Rifampicin

Indexed keywords

ADENOSINE DEAMINASE; ANTIBIOTIC AGENT; CREATININE; ETHAMBUTOL; GLOBIN; HEMOGLOBIN; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; BIOLOGICAL MARKER; TUBERCULOSTATIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG CLEARANCE RATIO; DRUG PENETRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PERICARDIUM; PH; PILOT STUDY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TUBERCULOUS PERICARDITIS; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; MIXED INFECTION; PERICARDIAL EFFUSION; PERICARDITIS, TUBERCULOUS; PERMEABILITY; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; BIOMARKERS; CD4 LYMPHOCYTE COUNT; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PERICARDIAL EFFUSION; PERICARDITIS, TUBERCULOUS; PERICARDIUM; PERMEABILITY; YOUNG ADULT;

EID: 84958932222     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.09.025     Document Type: Article

References (36)

1. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., Drusano G.L. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 2007, 44:79-86.
2. Ben-Horin S., Shinfeld A., Kachel E., et al. The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. Am. J. Med. 2005, 118:636-640.
3. Cherian G. Diagnosis of tuberculous etiology in pericardial effusions. Postgrad. Med. J. 2004, 80:262-266.
4. Chigutsa E., Pasipanodya J.G., Visser M.E., et al. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. Antimicrob. Agents Chemother. 2015, 59:38-45.
5. Conte J.E., Golden J.A., Duncan S., et al. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 1999, 43:1329-1333.
6. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 1998, 26:1-10.
7. Gumbo T. Chemotherapy of Tuberculosis, Mycobacterium avium Complex Disease, and Leprosy. Goodman & Gilman's The Pharmacological Basis of Therapeutics 2011, McGraw Hill Medical, New York, NY. L.L. Brunton, B. Chabner, B. Knollmann (Eds.).
8. Gumbo T., Louie A., Deziel M.R., et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob. Agents Chemother. 2007, 51:3781-3788.
9. Gumbo T., Louie A., Liu W., et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob. Agents Chemother. 2007, 51:2329-2336.
10. Gumbo T., Siyambalapitiyage Dona C.S., Meek C., et al. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 2009, 53:3197-3204.
11. Gumbo T., Chigutsa E., Pasipanodya J., et al. The pyrazinamide susceptibility breakpoint above which combination therapy fails. J. Antimicrob. Chemother. 2014, 69:2420-2425.
12. Gumbo T., Pasipanodya J.G., Wash P., et al. Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. Antimicrob. Agents Chemother. 2014, 58:6111-6115.
13. Gumbo T., Angulo-Barturen I., Ferrer-Bazaga S. Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J. Infect. Dis. 2015, 211(Suppl. 3):S96-S106.
14. Gumbo T., Pasipanodya J.G., Nuermberger E., Romero K., Hanna D. Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm. Clin. Infect. Dis. 2015, 61(Suppl 1):S18-S24.
15. Gumbo T., Pasipanodya J.G., Romero K., Hanna D., Nuermberger E. Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes. Clin. Infect. Dis. 2015, 61(Suppl 1):S25-S31.
16. Hall R.G., Swancutt M.A., Meek C., Leff R., Gumbo T. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob. Agents Chemother. 2012, 56:1502-1507.
17. Kopcinovic L.M., Culej J. Pleural, peritoneal and pericardial effusions - a biochemical approach. Biochem. Med. (Zagreb) 2014, 24:123-137.
18. Mayosi B.M., Burgess L.J., Doubell A.F. Tuberculous pericarditis. Circulation 2005, 112:3608-3616.
19. Mayosi B.M., Wiysonge C.S., Ntsekhe M., et al. Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. BMC Infect. Dis. 2006, 6:2.
20. Mayosi B.M., Wiysonge C.S., Ntsekhe M., et al. Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S. Afr. Med. J. 2008, 98:36-40.
21. Mayosi B.M., Ntsekhe M., Bosch J., et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N. Engl. J. Med. 2014, 371:1121-1130.
22. McDermott W., Tompsett R. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am. Rev. Tuberc 1954, 70:748-754.
23. Pandie S., Peter J.G., Kerbelker Z.S., et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-gamma in a high burden setting: a prospective study. BMC Med. 2014, 12:101.
24. Pasipanodya J., Gumbo T. An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob. Agents Chemother. 2011, 55:24-34.
25. Pasipanodya J.G., Srivastava S., Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin. Infect. Dis. 2012, 55:169-177.
26. Pasipanodya J.G., McIlleron H., Burger A., et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J. Infect. Dis. 2013, 208:1464-1473.
27. Pasipanodya JG, Mubanga M, Ntsekhe N, Pandie P, Beki T, Magazi BT, Gumedze F, Myer L, Gumbo T, Mayosi BM. Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality. EBiomed.
28. Reuter H., Burgess L., van V.W., et al. Diagnosing tuberculous pericarditis. QJM 2006, 99:827-839.
29. Srivastava S., Musuka S., Sherman C., et al. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 2010, 201:1225-1231.
30. Srivastava S., Pasipanodya J.G., Meek C., et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J. Infect. Dis. 2011, 204:1951-1959.
31. Srivastava S., Sherman C., Meek C., Leff R., Gumbo T. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob. Agents Chemother. 2011, 55:5085-5089.
32. Te Brake L.H., Ruslami R., Later-Nijland H., et al. Exposure to total and protein-unbound rifampin is not affected by malnutrition in indonesian tuberculosis patients. Antimicrob. Agents Chemother. 2015, 59:3233-3239.
33. Woo J., Cheung W., Chan R., et al. In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein. Clin. Biochem. 1996, 29:175-177.
34. Zeitlinger M.A., Derendorf H., Mouton J.W., et al. Protein binding: do we ever learn?. Antimicrob. Agents Chemother. 2011, 55:3067-3074.
35. Zhang Y1., Mitchison D. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 2003, 7:6-21.
36. Zhang Y., Permar S., Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 2002, 51:42-49.